Atrium Therapeutics announced nonclinical data for its lead therapy ATR 1072 showing reversal of cardiac glycogen accumulation and improvement in hypertrophy in a mouse model of PRKAG2 syndrome. The company plans to present these findings at the American Heart Association Scientific Sessions 2026 and expects initial Phase 1/2 clinical proof-of-concept data in the second half of 2027.
Atrium Therapeutics filed an amendment to correct the post-offering share count following a PIPE transaction involving 5,170,384 shares of common stock and pre-funded warrants for 1,134,930 shares. The company expects to have 21,571,507 shares outstanding after the closing of the offering and the settlement of spin-off related equity awards.
Atrium Therapeutics entered into a securities purchase agreement for a $50 million private placement (PIPE) involving the sale of 5,170,384 common shares and pre-funded warrants for 1,134,930 shares. The offering was priced at $7.93 per share and included participation from several institutional investors. Proceeds will be used to fund the development of lead product candidates and extend the company's cash runway through 2028.
Value
$50M
Counterparty
Sirenia Capital Management LP, Aberdeen Investments, Montanova, Sessa Capital, Casdin Capital